The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Diffuse Alveolar Hemorrhage (DAH) Syndrome

A life-threatening clinical syndrome of widespread bleeding into the alveolar spaces presenting with hemoptysis, anemia, hypoxemia, and diffuse alveolar opacities; etiologies include immune (ANCA-vasculitis, Goodpasture, lupus), bland (anticoagulation, mitral stenosis), and DAD (drug-induced, infection, transplant).

Before your visit, please confirm that services related to this topic are available at our hospital via WhatsApp or by calling +90 850 321 50 00.

Written by: Saygı Hospital Health Guide Editorial Board
Published:

This content is for general information; please consult your physician for diagnosis and treatment.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göğüs Hastalıkları department. Book Appointment →

What is Diffuse Alveolar Hemorrhage (DAH) Syndrome?

Diffuse alveolar hemorrhage (DAH) is a syndrome of widespread bleeding from the pulmonary microcirculation (capillaries, arterioles, venules) into the alveolar spaces. It is a medical emergency with mortality up to 50 percent if untreated. Defining features: hemoptysis (absent in 33 percent — be vigilant), bilateral pulmonary infiltrates on chest imaging, anemia (often progressive over hours), hypoxemic respiratory failure, and BAL with progressively bloodier returns from sequential aliquots (gold-standard diagnostic, 30 percent or more red cells in last aliquot or hemosiderin-laden macrophages > 20 percent for chronic bleeding).

Pathologic classification: (1) Pulmonary capillaritis (most common immune cause) — neutrophilic infiltration of alveolar capillaries with fibrinoid necrosis; etiologies: ANCA-associated vasculitis (granulomatosis with polyangiitis = Wegener, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis = Churg-Strauss), anti-GBM disease (Goodpasture syndrome), SLE, antiphospholipid syndrome, IgA vasculitis (Henoch-Schönlein), cryoglobulinemic vasculitis, polyangiitis with mixed connective tissue disease, drug-induced (propylthiouracil, hydralazine, levamisole-contaminated cocaine); (2) Bland DAH (no inflammation) — anticoagulants (warfarin, DOACs, heparin), antiplatelets, thrombolytics, severe coagulopathy, mitral stenosis with elevated PCWP, mitral regurgitation, idiopathic pulmonary hemosiderosis; (3) Diffuse alveolar damage with DAH — acute respiratory distress syndrome, drug-induced (amiodarone, nitrofurantoin, sirolimus, all-trans-retinoic acid, mTOR inhibitors), bone marrow / hematopoietic stem cell transplant (DAH 1–4 percent of HSCT, very high mortality), invasive infection (CMV, aspergillosis, leptospirosis, dengue), radiation pneumonitis acute.

Diagnosis: comprehensive serology (ANCA-MPO, ANCA-PR3, anti-GBM, ANA, anti-dsDNA, anti-Sm, complement C3/C4, antiphospholipid antibodies, cryoglobulins, ASO, complement), HRCT chest (bilateral ground-glass opacities and consolidations with central predominance, sparing of subpleural areas), bronchoscopy with sequential BAL (essential — confirms DAH and excludes infection), urinalysis (red cell casts in pulmonary-renal syndrome — Goodpasture, vasculitis), kidney biopsy (rapidly progressive glomerulonephritis), surgical lung biopsy if etiology unclear after non-invasive workup.

Symptoms

Hemoptysis (absent in 33 percent — DAH without hemoptysis is critical to recognize)
Acute or subacute dyspnea progressing to respiratory failure
Cough
Hypoxemia (often severe, may require mechanical ventilation)
Anemia (often progressive over hours to days)
Bilateral pulmonary infiltrates on chest imaging
Constitutional symptoms: fever, fatigue, weight loss (vasculitis)
Pulmonary-renal syndrome features: hematuria, RBC casts, AKI (Goodpasture, ANCA-vasculitis)
Sinus, ear, joint, skin findings depending on underlying disease (vasculitis)

Risk Factors

Known autoimmune disease (SLE, ANCA-vasculitis, anti-GBM)
Anticoagulant or antiplatelet therapy
Mitral valve disease
Hematopoietic stem cell transplant or solid organ transplant
Drug exposure (propylthiouracil, hydralazine, amiodarone, nitrofurantoin, sirolimus, all-trans-retinoic acid)
Cocaine use (levamisole contamination causes ANCA-positive vasculitis)
Severe infection (CMV, leptospirosis, dengue, hantavirus)
Coagulopathy (DIC, severe thrombocytopenia, liver failure)
Recent bone marrow transplant (engraftment syndrome)
Family history of pulmonary-renal syndrome

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Hemoptysis (cough with blood) — emergent evaluation
  • Sudden severe shortness of breath with bloody sputum
  • Anemia with bilateral lung infiltrates — emergency
  • Hematuria with pulmonary symptoms (suspected pulmonary-renal syndrome)
  • Known autoimmune disease with new respiratory or renal symptoms
  • Patient on anticoagulation with hemoptysis
  • Post-transplant patient with respiratory symptoms
  • Drop in hemoglobin in critically ill patient with respiratory failure

Treatment Methods

01
Initial stabilization: airway, breathing, circulation; intubation and mechanical ventilation if respiratory failure (low tidal volume lung-protective strategy); transfusion of packed red cells, platelets, FFP as needed; reverse anticoagulation (vitamin K, PCC for warfarin; idarucizumab for dabigatran; andexanet alfa for factor Xa inhibitors)
02
Urgent diagnostic workup: ANCA-MPO and ANCA-PR3, anti-GBM, ANA, anti-dsDNA, complement, antiphospholipid, urinalysis with microscopy, CBC, coagulation studies, blood cultures, sputum / BAL cultures including viral PCR, HRCT chest, bronchoscopy with sequential BAL (sequential aliquots of progressively bloodier return = DAH); kidney biopsy if pulmonary-renal syndrome suspected
03
Empiric high-dose corticosteroids while awaiting serology: IV methylprednisolone 1 g/day for 3 days, then prednisone 1 mg/kg/day taper
04
ANCA-vasculitis (most common immune cause): induction therapy with rituximab 375 mg/m² weekly x 4 (RAVE / RITUXVAS trials, preferred for relapsing or younger patients) OR cyclophosphamide IV 15 mg/kg every 2 weeks x 3 then every 3 weeks x 3 (CYCLOPS protocol); plus high-dose corticosteroids; maintenance with azathioprine or rituximab
05
Anti-GBM disease (Goodpasture syndrome): plasmapheresis (TPE) daily for 14 days or until anti-GBM negative, plus oral cyclophosphamide 2 mg/kg/day plus high-dose corticosteroids; emergent treatment essential as anti-GBM has very poor renal recovery if delayed
06
SLE-DAH: high-dose corticosteroids plus cyclophosphamide or rituximab; consider IVIG and plasmapheresis for refractory cases; mycophenolate for maintenance
07
Bland DAH: reverse coagulopathy, address underlying cause (mitral valve repair, discontinue anticoagulant); supportive care
08
DAD-associated DAH: identify and remove offending drug, treat infection, supportive care; recombinant activated factor VII (rFVIIa) inhaled or systemic for refractory bleeding (limited evidence, used in transplant DAH)
09
Long-term: monitor for relapse (vasculitis, anti-GBM), maintain immunosuppression, screen for malignancy (cyclophosphamide bladder cancer, lymphoma), pneumocystis prophylaxis (TMP-SMX), bone protection (calcium, vitamin D, bisphosphonate)

Which Department to Visit?

You can visit our Göğüs Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Göğüs Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Asthma

Göğüs Hastalıkları

Asthma is characterized by wheezing, coughing and shortness of breath attacks; with proper treatment it can be kept under control.

COPD (Chronic Obstructive Pulmonary Disease)

Göğüs Hastalıkları

COPD is an irreversible lung disease characterized by shortness of breath and chronic cough; quitting smoking slows its progression.

Pneumonia

Göğüs Hastalıkları

Pneumonia presents with high fever, cough and shortness of breath; the vast majority recover with appropriate antibiotic treatment.

Tuberculosis (TB)

Göğüs Hastalıkları

Tuberculosis presents with weeks-to-months of cough, fever, and night sweats; early diagnosis and treatment lead to full recovery.

Pleural Effusion

Göğüs Hastalıkları

Pleural effusion is the accumulation of excess fluid in the pleural space, resulting from imbalances in fluid production and removal, and represents a manifestation of diverse cardiopulmonary, infectious, and malignant disorders.

Pneumothorax

Göğüs Hastalıkları

Pneumothorax is the presence of air in the pleural space resulting in partial or complete lung collapse, classified as spontaneous (primary/secondary), traumatic, or iatrogenic, with tension pneumothorax representing a life-threatening emergency.

Bronchitis (Acute and Chronic)

Göğüs Hastalıkları

Acute bronchitis is mostly viral and resolves spontaneously, while chronic bronchitis is a smoking-related component of COPD.

Bronchiectasis

Göğüs Hastalıkları

Bronchiectasis is a chronic respiratory disease characterized by permanent, abnormal dilation of bronchi with associated destruction of muscular and elastic components of airway walls, resulting in impaired mucociliary clearance and recurrent infection.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.